trial · primary record
Tumor associated antigen lymphocytes (TAA-CTL)
Solid Tumors
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 36 |
| Primary completion | 2027-12 |
| Primary endpoint | Incidence of Product-Emergent Adverse Events |
| Registry ID | NCT02789228 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:35.532Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02789228
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.